Rapid Lung Function Improvement with Lebrikizumab in Patients with Uncontrolled Asthma

Rapid Lung Function Improvement with Lebrikizumab in Patients with Uncontrolled Asthma

Methods We conducted a pooled analysis of three trials (NCT00930163/NCT01545440/NCT01545453) including 565 patients with moderate-to-severe uncontrolled asthma receiving ICS (200-2000 μg/day fluticasone propionate or equivalent), >=1 additional controller (>90% LABA), pre-bronchodilator FEV1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2016-02, Vol.137 (2), p.AB13-AB13
Hauptverfasser: Corren, Jonathan, MD, Hanania, Nicola A., MD, Korenblat, Phillip E., MD, FAAAAI, Olssen, Julie K., MD, MS, Kamath, Nikhil, MD, Gray, Sarah, PhD, Martin, Nicolas, Holweg, Cecile T.J., PhD, Matthews, John G., MB, BS, MRSCP, PhD, Limb, Susan L., MD, Korom, Stephan
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Asthma
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Methods We conducted a pooled analysis of three trials (NCT00930163/NCT01545440/NCT01545453) including 565 patients with moderate-to-severe uncontrolled asthma receiving ICS (200-2000 μg/day fluticasone propionate or equivalent), >=1 additional controller (>90% LABA), pre-bronchodilator FEV1 40-80% predicted and >=12% FEV1 reversibility.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2015.12.043